Browsing Tag
Harbour BioMed
4 posts
Harbour BioMed FDA IND clearance puts HBM7004 into the clinical spotlight as bispecific oncology race intensifies
Harbour BioMed has FDA clearance, but HBM7004 must now prove whether its B7H4xCD3 design can translate platform science into clinical value.
Bristol Myers Squibb signs $1.1bn multi-specific antibody discovery deal with Harbour BioMed
Harbour BioMed signed a $1.125B discovery deal with Bristol Myers Squibb to co-develop multi-specific antibodies. Read the full strategic breakdown now.
AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy.
Harbour BioMed resubmits BLA for batoclimab to China’s NMPA for generalized myasthenia gravis
Harbour BioMed (HKEX: 02142), a prominent global biopharmaceutical company, has announced the resubmission of the Biologics License Application…